Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: A systematic review and meta-analysis

British Journal of Cancer

Volumn 113, Issue 10, 2015, Pages 1519-1528

  Kuan, Feng Che ^a,b   Kuo, Liang Tseng ^a,c   Chen, Min Chi ^d   Yang, Cheng Ta ^a,d   Shi, Chung Sheng ^d   Teng, David ^e   Lee, Kuan Der ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e University of California   (United States)

Author keywords

first line EGFR; NSCLC; overall survival; TKI

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; EXON; GENE DELETION; GENE MUTATION; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MUTATION; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84947487341     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.356     Document Type: Article

References (53)

1. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750-3757.
2. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4(9): 1046-1061.
3. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled Clin Trials 7(3): 177-188.
4. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109): 629-634.
5. EURTAC (2013) Highlights of Prescribing Information. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021743s018lbl.pdf (accessed on 20 October 2014).
6. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpon V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874.
7. Furuyama K, Harada T, Iwama E, Shiraishi Y, Okamura K, Ijichi K, Fujii A, Ota K, Wang S, Li H, Takayama K, Giaccone G, Nakanishi Y (2013) Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci 104(5): 584-589.
8. GLOBOCAN (2008) Country Fast Stat. Available at http://globocan.iarc.fr./factsheet.asp (accessed on 7 November 2014).
9. Gao G, Ren S, Li A, Xu J, Xu Q, Su C, Gou J, Deng Q, Zhou C (2012) Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int J Cancer 131(5): E822-E829.
10. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a metaanalysis. Stat Med 21(11): 1539-1558.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414): 557-560.
12. Higgins JP, Green S eds. (2008) Cochrane collaboration. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons: West Sussex, England.
13. Hirsch FR, Bunn PA Jr (2009) EGFR testing in lung cancer is ready for prime time. Lancet Oncol 10(5): 432-433.
14. Hata A, Yoshioka H, Fujita S, Kunimasa K, Kaji R, Imai Y, Tomii K, Iwasaku M, Nishiyama A, Ishida T, Katakami N (2010) Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. J Thorac Oncol 5: 1524-1528.
15. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun JS, Suh C, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never smokers with adenocarcinoma of the lung. J Clin Oncol 30(10): 1122-1128.
16. Haaland B, Tan PS, de Castro Jr G, Lopes G (2014) Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol 9(6): 805-811.
17. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizama H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. North-East Japan Study Group (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 24: 54-59.
18. Ichihara E, Hotta K, Nogami N, KuyamaS, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K (2015) Phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol 10(3): 486-491.
19. Kosaka T, Yamaki E, Mogi A, Kuwano H (2011) Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-smallcell lung cancer. J Biomed Biotechonol 2011: 165214.
20. Katakami N, Morita S, Yoshioka H, Seto T, Urata Y, Satouchi M, Iwamoto Y, Otsuka K, Ikeda N, Takahashi T, Daga H, Oguri T, Goto I, Uchida J, Sugawara S, Kitagawa C, Kozuki T, Inata J, Nakagawa K, Nakanishi Y (2014) Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma. J Clin Oncol 32(Suppl): abstr 8041.
21. Kato T, Seto T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Harada R, Fukuoka M, Yamamoto N (2014) Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC): an open-label randomized trial. J Clin Oncol 32: abstract 8005.
22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settelman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Eng J Med 350(21): 2129-2139.
23. Li D, Ambrogio L, Shimamura T, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Retting WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34): 4702-4711.
24. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Natl Cancer Inst 105(9): 595-605.
25. Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, Xue C, Zhang J, May Y, Zhou T, Yan Y, Hou X, Qin T, Dinglin X, Tian Y, Huang P, Huang Y, Zhao H, Zhang L (2014) Network meta-analysis of erlotinib, gefitinib, afatinib, and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One 9(2): e85245.
26. Lu RL, Hu CP, Yang HP, Li YY, Gu QH, Wu L (2014) Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma. Patho Oncol Res 20: 445-451.
27. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824.
28. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyoung B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 361(10): 947-957.
29. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizama H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Eng J Med 362(25): 2380-2388.
30. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukouka M. West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2): 121-128.
31. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukouka M (2012) Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 30(Suppl): abstract 7521.
32. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA (2011) Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 15(17): 1616-1622.
33. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herma P, Kaye FJ, Linderman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500.
34. Paz-Ares L, Soulières D, Moecks J, Bara I, Mok T, Klughammer B (2014) Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. J Cell Mol Med 18(8): 1519-1539.
35. Review Manager (2014) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration.
36. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Coho M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munõz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC). Lancet Oncol 13(3): 239-246.
37. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3): 169-181.
38. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advancedstage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
39. Sekine A, Kato T, Hagiwara E, Shinohara T, Komagata T, Iwasawa T, Satoh H, Tamura K, Kasamatsu T, Hayashihara K, Saito T, Takahashi H, Ogura T (2012) Metastatic brain tumors from non-small-cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 77(1): 64-69.
40. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee VH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27): 3327-3334.
41. Sebastian M, Schmittel A, Reck M (2014) First-line treatment of EGFRmutated non-small cell lung cancer: critical review on study methodology. Eur Respir Rev 23(131): 92-105.
42. Skrickova J, Bortlicek Z, Hejduk K, Pesek M, Kolek V, Koubkova L, Tomiskova M, Roubec J, Havel L, Salajka F (2014) The results of gefitinib in front-line treatment of Caucasian patients with NSCLC in the Czech Republic: analysis according to activated mutations location. Transl Lung Cancer Res 3(5): AB010.
43. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC (2008) Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14: 4877-4882.
44. Wu Y, Liam C, Zhou C, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Zhu Y, Qin S, Huang C, Pan H, Liang H, Li E, How SH, Jiang G, Fernando MC, Chen M, Zuo Y, Ladrera G (2013) First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): interim analyses from the phase 3, open-label, ENSURE study. J Thoracic Oncol 8(Suppl 2): S603.
45. Wang H, Huang J, Yu X, Han S, Yan X, Sun S, Zhu X (2014) Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: A meta-analysis. J Cancer Res Clin Oncol 140(11): 1901-1909.
46. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open label, randomised phase 3 trial. Lancet Oncol 15(2): 213-222.
47. Yoshida T, Yamada K, Azuma K, Kawahara A, Abe H, Hattori S, Yamashita F, Zaizen Y, Kage M, Hoshino T (2013) Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: A retrospective analysis. Med Oncol 30(1): 349.
48. Yang JC, Sequist LV, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Geater SL, Zhou C, Massey D, Zazulina V, Wu YL (2014) Overall survival in patients with advanced non-small cell lung cancer harboring common (Del19/L858R) epidermal growth factor receptor mutations: pooled analysis of two large open-label phase III studies (LUX-lung 3 and LUX-lung 6) comparing afatinib with chemotherapy. J Clin Oncol 32(suppl): abstract 8004.
49. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou X, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomized, phase 3 trials. Lancet Oncol 16(2): 141-151.
50. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Lou Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG0802): A multi-centre, open-label, randomised, phase 3 study. Lancet Oncol 12(8): 735-742.
51. Zhou C, Wu Y, Liu XQ, Wang C, Chen G, FENG J, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Lou Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q (2012) Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30(Suppl): abstract 485s.
52. Zeng Z, Yan HH, Zhang XC, Zhong WZ, He YY, Guan JL, Niu FY, Xie Z, Huang YS, Xu CR, Dong S, Wu YL (2014) Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline tyrosine kinase inhibitor. Lung Cancer 86: 219-224.
53. Zhang Y, Sheng J, Kang S, Fang W, Yan Y, Hu Z, Hong S, Wu X, Qin T, Liang W, Zhang L (2014) Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: A meta-analysis. PLoS One 9(9): e107161.